Biolife Solutions Inc Stock Price, News & Analysis

BioLife Solutions (NASDAQ: BLFS) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will host a conference call and live webcast the same day at 4:30 PM ET (1:30 PM PT) to present an overview of financial results and a general business update.

Investors can access the live webcast at the company Investor Relations page and join the call via toll-free 1-833-630-0431 or international 1-412-317-1808. A replay will be available about two hours after the call and archived on the investor site for 90 days.

BioLife Solutions (Nasdaq: BLFS) announced the sale of its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies (f/k/a SAVSU Technologies), to Peli BioThermal for $25.5 million in cash, subject to customary adjustments.

The company said the divestiture will streamline its product portfolio and operations to concentrate resources on high-margin recurring revenue in its core cell and gene therapy tools and services business.

BioLife Solutions (Nasdaq: BLFS) reported strong Q2 2025 financial results with total revenue of $25.4 million, up 29% year-over-year. Cell Processing revenue reached $23.0 million, increasing 28% from Q2 2024. The company achieved a GAAP gross margin of 62% and adjusted EBITDA of $6.1 million (24% of revenue).

Despite reporting a GAAP net loss of $15.8 million, largely due to a one-time $15.5 million IPR&D expense from the PanTHERA acquisition, BioLife raised its 2025 revenue guidance to $100.0-103.0 million. The company's biopreservation media is now embedded in 16 approved therapies and supports over 250 clinical trials, including 30+ in Phase III.

[ "Cell Processing revenue grew 28% year-over-year to $23.0 million", "Strong adjusted EBITDA of $6.1 million, representing 24% of revenue", "Raised full-year 2025 revenue guidance to $100.0-103.0 million", "Biopreservation media embedded in 16 approved therapies", "70% market share in commercially sponsored clinical trials", "Healthy cash position of $100.2 million as of June 30, 2025" ]

BioLife Solutions (NASDAQ: BLFS), a leading bioproduction products supplier for cell and gene therapy, has made a $2 million strategic investment in Pluristyx through convertible notes. The investment includes a board observer seat and potential future acquisition rights.

Pluristyx, a Seattle-based company, develops innovative induced pluripotent stem cell (iPSC) products for cell therapy developers. The investment aligns with BioLife's strategy of exploring biological assays as a product portfolio expansion, following similar investments in Sexton and PanTHERA.

BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, will release its second quarter 2025 financial results after market close on Thursday, August 7, 2025.

The company will host a conference call and webcast at 4:30 PM ET where management will discuss financial results and provide a business update. Investors can access the webcast through BioLife's website or join via phone using the provided toll-free numbers.

BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, has announced its participation in five upcoming investor conferences in May and June 2025. The company will attend the Craig-Hallum Institutional Investor Conference (May 28, Minneapolis), Benchmark Healthcare House Call Virtual Conference (May 29), Jefferies Global Life Sciences Conference (June 3-5, New York), Wolfe Research Small & Mid-Cap Conference (June 5, New York), and Northland Growth Conference (June 25, Virtual).

BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, has provided updated dial-in information for their earnings call scheduled for today at 4:30pm ET. U.S. participants can dial 1-833-630-0431, while international callers should use 1-412-317-1808.

BioLife Solutions specializes in providing solutions that maintain the health and function of biological materials throughout the collection, development, manufacturing, and distribution processes, supporting the commercialization of new therapies in the CGT market.

BioLife Solutions (NASDAQ: BLFS) reported strong Q1 2025 financial results, with total revenue reaching $23.9 million, up 30% year-over-year. Cell Processing revenue grew 33% to $21.6 million. The company achieved a GAAP gross margin of 63% and reported a reduced GAAP net loss of $0.4 million, with adjusted EBITDA of $5.7 million (24% of revenue). BioLife's biopreservation media is now embedded in 17 commercial cell and gene therapies, with 10 additional approvals expected in the next 12 months. The company completed the acquisition of PanTHERA CryoSolutions in April 2025. BioLife affirmed its 2025 revenue guidance of $95.5-99.0 million, representing 16-20% growth. The company maintains a strong financial position with $107.6 million in cash and marketable securities.

BioLife Solutions, a key player in the cell and gene therapy (CGT) market, has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company, which specializes in bioproduction products and services, will release its Q1 2025 results after market close on Thursday, May 8, 2025.

The company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) on the same day. Management will present the financial results and provide a business update. Investors and interested parties can access the webcast through the company's Investor Relations page or join via phone using the toll-free numbers: 1-877-344-7529 (domestic) or 1-412-317-0088 (international).

A replay of the webcast will be available approximately two hours after the call and will remain accessible on the investor relations website for 90 days.